TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10559703

Group type: EXPERIMENTAL
Intervention: Tryptophan enhancement (amino acid drink enhanced with tryptophan)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (amino acid drink depleted of tryptophan)
Number of subjects: 28
Study: 8909663

Group type: EXPERIMENTAL
Intervention: metoclopramide 10 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: cyclizine 50 mg
Number of subjects: 204

Group type: COMPARATOR
Intervention: no antiemetic
Number of subjects: 204
Study: 2069491

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (100 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 22
Study: 6402162

Group type: EXPERIMENTAL
Intervention: Reinforcing verbal advice with a booklet
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: Reinforcing verbal advice with a booklet and nicotine chewing gum
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: Reinforcing verbal advice with a booklet and placebo chewing gum
Number of subjects: 1550

Group type: COMPARATOR
Intervention: Verbal advice alone
Number of subjects: 1550
Study: 31113442

Group type: EXPERIMENTAL
Intervention: Novel self-management intervention led by health professionals
Number of subjects: 9

Group type: COMPARATOR
Intervention: Technological supporting tool
Number of subjects: 9
Study: 26418434

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 23398452

Group type: EXPERIMENTAL
Intervention: Online ABD learning package consisting of symptom‐based decision‐making pathways underpinned by a ratified ABD evidence‐based guideline
Number of subjects: 248

Group type: COMPARATOR
Intervention: Online dummy package
Number of subjects: 248
Study: 21242788

Group type: EXPERIMENTAL
Intervention: Initial trophic enteral nutrition (10 mL/hr)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Initial full-energy enteral nutrition
Number of subjects: 200
Study: 19526159

Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(‐1) propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) metoclopramide
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline solution (Control)
Number of subjects: 60
Study: 18001178

Group type: EXPERIMENTAL
Intervention: Ablation with 1.1 GBq (n = 36) or 3.7 GBq (131)I (n = 58)
Number of subjects: 136

Group type: COMPARATOR
Intervention: No ablative therapy (n = 42)
Number of subjects: 136
Study: 19777723

Group type: EXPERIMENTAL
Intervention: Home chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based HPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospital-based HPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups of HPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Service delivery issues
Number of subjects: 0
Study: 12151468

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 to 3.5 mg per day)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 9849978

Group type: EXPERIMENTAL
Intervention: Group A (concomitant injections of M-M-R II, VARIVAX, and TETRAMUNE)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Group B (VARIVAX given 6 weeks after M-M-R II and TETRAMUNE)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Group A (VARIVAX injection sites)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Group B (VARIVAX injection sites)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Group A (TETRAMUNE sites)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Group B (TETRAMUNE sites)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: M-M-R II alone
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: M-M-R II with VARIVAX
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: VARIVAX alone
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: M-M-R II and TETRAMUNE together (Days 0 to 3)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: M-M-R II and TETRAMUNE together (Days 7 to 21)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: VARIVAX alone (Days 0 to 3)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: VARIVAX alone (Days 7 to 21)
Number of subjects: 609
Study: 7507504

Group type: EXPERIMENTAL
Intervention: Acute reperfusion (1,309 patients)
Number of subjects: 1944

Group type: COMPARATOR
Intervention: No acute reperfusion (635 patients)
Number of subjects: 1944
Study: 2681578

Group type: EXPERIMENTAL
Intervention: Erythrocyte transfusion
Number of subjects: 16
Study: 805050

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg, 3 times daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31686199

Group type: EXPERIMENTAL
Intervention: SNZ TriBac
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28617807

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 0.5 mg/kg/tpd with β-lactam plus macrolide
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo with β-lactam plus macrolide
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo with β-lactam plus fluoroquinolone
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 0.5 mg/kg/tpd with β-lactam plus fluoroquinolone
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality in the per protocol population
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Overall treatment failure
Number of subjects: 106
Study: 25261629

Group type: EXPERIMENTAL
Intervention: Active cTBS
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham cTBS
Number of subjects: 29
Study: 23701738

Group type: EXPERIMENTAL
Intervention: Manualised CBT anger management intervention delivered by lay therapists
Number of subjects: 212
Study: 21275080

Group type: EXPERIMENTAL
Intervention: 3-Hydroxykynurenine (3-OHKY) levels
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clinical symptom scores
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Neurological symptoms
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 25
Study: 19713654

Group type: EXPERIMENTAL
Intervention: Bilateral stellate ganglion block with 8 ml 1% lidocaine solution
Number of subjects: 20
Study: 17908769

Group type: EXPERIMENTAL
Intervention: IL6‐174 G/G genotype
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: TNFA promoter genotypes ‐238 G/G and ‐376 G/G, TLR4 299 A/A genotype
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: TNFA‐238 G/G genotype or TNFA‐863 A allele carriage
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: IL10‐1082 A/A genotype
Number of subjects: 348
Study: 15531048

Group type: EXPERIMENTAL
Intervention: Low back pain patients
Number of subjects: 123

Group type: COMPARATOR
Intervention: Asymptomatic participants
Number of subjects: 123
Study: 11432712

Group type: EXPERIMENTAL
Intervention: Mailed test kit
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Kit request card
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Mailed test kit with information leaflet
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Kit request card with information leaflet
Number of subjects: 1000
Study: 9768403

Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manual phacofracture
Number of subjects: 60
Study: 7812483

Group type: EXPERIMENTAL
Intervention: Metal subcutaneous needle
Number of subjects: 63

Group type: COMPARATOR
Intervention: PTFE (Vialon) catheter
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Volume of medication injected per day
Number of subjects: 63
Study: 2315771

Group type: EXPERIMENTAL
Intervention: Ticarcillin disodium irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefoxitin sodium irrigation
Number of subjects: 0
Study: 340140

Group type: EXPERIMENTAL
Intervention: Antacid plus antispasmodic combination tablets (240 mg dried aluminium hydroxide, 144 mg magnesium hydroxide, 5 mg dicyclomine hydrochloride)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Aluminium hydroxide B.P. tablets (500 mg)
Number of subjects: 37
Study: 31080025

Group type: EXPERIMENTAL
Intervention: Compression with tranexamic acid
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Nasal packing (Merocel)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Simple nasal external compression (saline solution)
Number of subjects: 135
Study: 29714864

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pubovaginal sling (PVS)
Number of subjects: 100
Study: 25310681

Group type: EXPERIMENTAL
Intervention: Depressed walking style
Number of subjects: 39

Group type: COMPARATOR
Intervention: Happy walking style
Number of subjects: 39
Study: 24100766

Group type: EXPERIMENTAL
Intervention: Posterior surgical approach (Post)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Antero-lateral surgical approach (AntLat)
Number of subjects: 38
Study: 21663696

Group type: EXPERIMENTAL
Intervention: Exercise at preferred intensity
Number of subjects: 38

Group type: COMPARATOR
Intervention: Exercise at prescribed intensity
Number of subjects: 38
Study: 19067057

Group type: EXPERIMENTAL
Intervention: Low-pressure CO2 pneumoperitoneum
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard-pressure CO2 pneumoperitoneum
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 17992378

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment + brief psychological intervention (LSPI)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional pharmacological treatment (CT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Pharmacological treatment + guidance program (OG)
Number of subjects: 74
Study: 15095520

Group type: EXPERIMENTAL
Intervention: Combined injector/monitor device
Number of subjects: 15

Group type: COMPARATOR
Intervention: Syringes and separate glucose monitor
Number of subjects: 15
Study: 11028250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg qd
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg qd
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg qd
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg tid
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg tid
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sodium naproxen 550 mg bid
Number of subjects: 76
Study: 8746167

Group type: EXPERIMENTAL
Intervention: radioiodine therapy (aRIT)
Number of subjects: 53
Study: 1326349

Group type: EXPERIMENTAL
Intervention: Rifabutin (B) daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Rifampicin (R) daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 22
Study: 3912001

Group type: EXPERIMENTAL
Intervention: Epoprostenol (PGI2, 2‐8 ng kg‐1 min‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 6‐keto‐prostaglandin E1 (6‐keto‐PGE1, 7.5‐30 ng kg‐1 min‐1)
Number of subjects: 6
Study: 31847914

Group type: EXPERIMENTAL
Intervention: Morning levothyroxine (LT4) intake (60 min before breakfast)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Evening levothyroxine (LT4) intake (60 min after supper)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both morning and evening LT4 intake
Number of subjects: 91
Study: 29893057

Group type: EXPERIMENTAL
Intervention: Animated cartoons during ICS delivery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Black screen video during ICS delivery (Control)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (Black screen video)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Animated cartoons
Number of subjects: 50
Study: 26701116

Group type: EXPERIMENTAL
Intervention: FATmax training (exercise training at individualized FATmax intensities, 1 h per day, 5 days per week for 10 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: FATmax training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (lean boys)
Number of subjects: 26
Study: 24847745

Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/d
Number of subjects: 3109

Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/d
Number of subjects: 3109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3109
Study: 22265923

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50mg every day for 5 days (days 3-7 of cycle)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Letrozole 2.5mg every day for 5 days (days 3-7 of cycle)
Number of subjects: 750
Study: 19496398

Group type: EXPERIMENTAL
Intervention: 10% citric acid-3% ferric chloride (10-3)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 65% phosphoric acid (PA)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 3
Study: 17601060

Group type: EXPERIMENTAL
Intervention: 1% carteolol hydrochloride long-acting eye drops (instilled once a day in the morning for 8 weeks)
Number of subjects: 146

Group type: COMPARATOR
Intervention: 1% carteolol hydrochloride currently-prescribed eye drops (instilled twice a day for 8 weeks)
Number of subjects: 146
Study: 15743368

Group type: EXPERIMENTAL
Intervention: Didactic lecture (DL) + Interactive case-based seminar (ICBS) + PDA-based risk assessment tool
Number of subjects: 82

Group type: COMPARATOR
Intervention: Didactic lecture (DL)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Didactic lecture (DL) + Interactive case-based seminar (ICBS)
Number of subjects: 82
Study: 12516683

Group type: EXPERIMENTAL
Intervention: Reviparin sodium 3500 anti-Xa IU per day (group A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Reviparin sodium 4200 anti-Xa IU per day (group B)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Reviparin sodium 5950 anti-Xa IU per day (group C)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Reviparin sodium 7000 anti-Xa IU per day (group D)
Number of subjects: 65
Study: 9524995

Group type: EXPERIMENTAL
Intervention: Video-based educational intervention
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Regular clinic services (Control)
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: High-risk intervention group
Number of subjects: 2004

Group type: COMPARATOR
Intervention: High-risk controls (Control)
Number of subjects: 2004
Study: 7657280

Group type: EXPERIMENTAL
Intervention: Ursodiol (10 to 12 mg/kg at bedtime for 2 years)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Ursodiol
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 2651175

Group type: EXPERIMENTAL
Intervention: Ticlopidine-pentoxifylline combination
Number of subjects: 79

Group type: COMPARATOR
Intervention: Aspirin-dipyridamole-buflomedil
Number of subjects: 79

Group type: COMPARATOR
Intervention: Buflomedil-placebo
Number of subjects: 79
Study: 778563

Group type: EXPERIMENTAL
Intervention: Bromhexine (Bisolvon)
Number of subjects: 0
Study: 31654328

Group type: EXPERIMENTAL
Intervention: Upadacitinib extended-release formulations (four different formulations)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Upadacitinib immediate-release capsule formulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: External validation formulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cross-validation model
Number of subjects: 20
Study: 28026912

Group type: EXPERIMENTAL
Intervention: gemigliptin 50 mg once daily
Number of subjects: 219

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 219
Study: 25795697

Group type: EXPERIMENTAL
Intervention: Preferring medications
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Sickness absence
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Being referred to a physiotherapist/chiropractor
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Changing their lifestyle
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Wanting to keep living as usual only
Number of subjects: 740
Study: 23632142

Group type: EXPERIMENTAL
Intervention: Whole-home exercise intervention (training for care home staff and twice-weekly physiotherapist-led exercise group)
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Control intervention (depression awareness training programme for care home staff)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Whole-home exercise intervention
Number of subjects: 1054
Study: 21277231

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1500 mg daily divided in two doses for 12 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 16
Study: 19454839

Group type: EXPERIMENTAL
Intervention: 100mg EMIQ for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 24
Study: 17291170

Group type: COMPARATOR
Intervention: Internet-only treatment
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Internet + in-person support (I+IPS)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Internet-only treatment (completers)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Internet + in-person support (I+IPS) (completers)
Number of subjects: 123
Study: 15289593

Group type: EXPERIMENTAL
Intervention: Beating The Blues plus conventional care
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional care alone
Number of subjects: 48
Study: 10944552

Group type: EXPERIMENTAL
Intervention: Chest x-ray and sputum cytology every 4 months for 6 years
Number of subjects: 9211

Group type: COMPARATOR
Intervention: Usual-care arm (advised to receive tests annually)
Number of subjects: 9211
Study: 9072981

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 30% of peak maximal inspiratory pressure (PI,max) for 30 min daily, 6 days a week for 10 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT) at 10% of peak maximal inspiratory pressure (PI,max) for 30 min daily, 6 days a week for 10 weeks
Number of subjects: 20
Study: 8452171

Group type: EXPERIMENTAL
Intervention: Fleroxacin, 400 mg intravenously once a day
Number of subjects: 319

Group type: COMPARATOR
Intervention: Ceftazidime, 0.5‐2 g three times daily or 1‐2 g twice daily
Number of subjects: 319
Study: 3528241

Group type: EXPERIMENTAL
Intervention: squaric acid dibutylester
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: diphencyprone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: minoxidil
Number of subjects: 119

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 119
Study: 31506186

Group type: EXPERIMENTAL
Intervention: Patient-specific osteosynthesis
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional osteosynthesis and splint-based positioning
Number of subjects: 58
Study: 29482662

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Exercise intervention (EI)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 330
Study: 29037651

Group type: EXPERIMENTAL
Intervention: Ischemic compression (4 sessions)
Number of subjects: 19
Study: 26215765

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) of systolic blood pressure (SBP) defined as SD across SBP measurements (≥14.4 mm Hg)
Number of subjects: 25814

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) of diastolic blood pressure (DBP)
Number of subjects: 25814
Study: 24040947

Group type: EXPERIMENTAL
Intervention: A100 1.8 mL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: A100 3.6 mL
Number of subjects: 30
Study: 20829043

Group type: EXPERIMENTAL
Intervention: Annual digital mammography with MRI
Number of subjects: 348

Group type: COMPARATOR
Intervention: Annual digital mammography without MRI
Number of subjects: 348
Study: 18815979

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 14
Study: 16549077

Group type: EXPERIMENTAL
Intervention: Intragastric balloon distension of the fundus (0, 400, 600, 800 ml) before a standard meal intake
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intragastric balloon distension of the antrum (0 ml plus ID saline or ID fat, and 300 ml plus ID saline or ID fat)
Number of subjects: 24
Study: 12888872

Group type: EXPERIMENTAL
Intervention: Certoparin (8000 U anti-factor Xa, subcutaneous, twice daily for 10 to 14 days)
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH, intravenous, aPTT-adjusted for 5 to 8 days)
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Certoparin
Number of subjects: 1220

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 1220
Study: 10366166

Group type: EXPERIMENTAL
Intervention: High collar shoes
Number of subjects: 42

Group type: COMPARATOR
Intervention: College shoes
Number of subjects: 42

Group type: COMPARATOR
Intervention: Soft-soled shoes
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hard-soled shoes
Number of subjects: 42

Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 42
Study: 8737135

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1957404

Group type: EXPERIMENTAL
Intervention: Human serum albumin (hSA) 200 mg/ml
Number of subjects: 135

Group type: COMPARATOR
Intervention: Patient serum
Number of subjects: 135
Study: 7181489

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 10
Study: 31393225

Group type: EXPERIMENTAL
Intervention: Normocaloric gluten-free diet (GFD) for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normocaloric diet (CG)
Number of subjects: 60
Study: 31594736

Group type: COMPARATOR
Intervention: Single intravesical instillation (SIC) with epirubicin 50 mg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Maintenance intravesical chemotherapy (MIC) once weekly for 6 weeks plus once monthly for 1 year
Number of subjects: 74

Group type: COMPARATOR
Intervention: Single intravesical instillation (SIC)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Maintenance intravesical chemotherapy (MIC)
Number of subjects: 74